Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Spero Therapeutics (SPRO) Return on Invested Capital (2023 - 2025)

Spero Therapeutics' Return on Invested Capital history spans 3 years, with the latest figure at 0.14% for Q4 2025.

  • For Q4 2025, Return on Invested Capital rose 142.0% year-over-year to 0.14%; the TTM value through Dec 2025 reached 0.14%, up 142.0%, while the annual FY2025 figure was 0.12%, N/A changed from the prior year.
  • Return on Invested Capital reached 0.14% in Q4 2025 per SPRO's latest filing, up from 1.43% in the prior quarter.
  • In the past five years, Return on Invested Capital ranged from a high of 0.25% in Q4 2023 to a low of 1.43% in Q3 2025.
  • Average Return on Invested Capital over 3 years is 0.46%, with a median of 0.0% recorded in 2024.
  • Peak YoY movement for Return on Invested Capital: crashed -153bps in 2024, then soared 142bps in 2025.
  • A 3-year view of Return on Invested Capital shows it stood at 0.25% in 2023, then plummeted by -605bps to 1.28% in 2024, then soared by 111bps to 0.14% in 2025.
  • Per Business Quant, the three most recent readings for SPRO's Return on Invested Capital are 0.14% (Q4 2025), 1.43% (Q3 2025), and 1.28% (Q4 2024).